Late-stage study underway for BioMarin’s gene therapy for hemophilia A – Seeking Alpha
|
Late-stage study underway for BioMarin's gene therapy for hemophilia A
Seeking Alpha The first patient has been dosed in a Phase 3 clinical trial, GENEr8-1, assessing BioMarin Pharmaceutical's (NASDAQ:BMRN) gene therapy valoctocogene roxaparvovec (VR) in patients with hemophilia A. The study is the first of two registration trials that … |
